{"transactions":[{"id":698935,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:08.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":44477,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330508","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330508/ownership.xml","form_type":"4"}},{"id":698934,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:08.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Class A Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330508","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330508/ownership.xml","form_type":"4"}},{"id":698933,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:08.000Z","date":"2026-07-30","kind":"grant","planned":false,"acquired":true,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":44477,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Class A Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330508","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330508/ownership.xml","form_type":"4"}},{"id":698932,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:08.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":44477,"derivative":{"exercise_price":8.15,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330508","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330508/ownership.xml","form_type":"4"}},{"id":698931,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:08.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":0,"derivative":{"exercise_price":8.15,"expiration_date":"2036-07-07","underlying":"Class A Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330508","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330508/ownership.xml","form_type":"4"}},{"id":698930,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:08.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":51890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":51890,"derivative":{"exercise_price":4,"expiration_date":"2033-09-18","underlying":"Common Stock","underlying_shares":51890},"source":{"system":"sec-edgar","filing":"0001193125-26-330508","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330508/ownership.xml","form_type":"4"}},{"id":698929,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:08.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":0,"derivative":{"exercise_price":4,"expiration_date":"2033-09-18","underlying":"Class A Common Stock","underlying_shares":51890},"source":{"system":"sec-edgar","filing":"0001193125-26-330508","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330508/ownership.xml","form_type":"4"}},{"id":746239,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T20:00:05.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":24372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":24372,"derivative":{"exercise_price":14.31,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":24372},"source":{"system":"sec-edgar","filing":"0001193125-26-261637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526261637/ownership.xml","form_type":"4"}},{"id":779287,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5748,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":59.86,"underlying":"Common Stock","underlying_shares":5748},"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779286,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":57.2,"underlying":"Common Stock","underlying_shares":27600},"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779285,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7441,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":51.71,"underlying":"Common Stock","underlying_shares":7441},"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779284,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":47.28,"underlying":"Common Stock","underlying_shares":8554},"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779283,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11199,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":31.91,"underlying":"Common Stock","underlying_shares":11199},"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779282,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":26.13,"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779281,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14684,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":25.12,"underlying":"Common Stock","underlying_shares":14684},"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779280,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3877,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779279,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779278,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7961,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779277,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5744,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779276,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3062,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":779275,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:31:48.000Z","date":"2026-05-14","kind":"other","planned":false,"acquired":false,"shares":30666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,"},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526224618/ownership.xml","form_type":"4"}},{"id":951634,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:36:11.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":14684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 1, 2026. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant."}],"balance_after":14684,"derivative":{"exercise_price":25.12,"expiration_date":"2033-12-31","underlying":"Common Stock","underlying_shares":14684},"source":{"system":"sec-edgar","filing":"0001492422-26-000010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000149242226000010/form4.xml","form_type":"4"}},{"id":951633,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-01-05T21:36:11.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":7961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock unit was granted on January 1, 2026. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election."}],"balance_after":30666,"source":{"system":"sec-edgar","filing":"0001492422-26-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000149242226000010/form4.xml","form_type":"4"}},{"id":1117974,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:12:55.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.05,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-083734","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000095017025083734/ownership.xml","form_type":"4"}},{"id":1314918,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-03T21:19:39.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":11199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 1, 2025. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant."}],"balance_after":11199,"derivative":{"exercise_price":31.91,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":11199},"source":{"system":"sec-edgar","filing":"0001127602-25-000425","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000112760225000425/form4.xml","form_type":"4"}},{"id":1314917,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-01-03T21:19:39.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":6267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock unit was granted on January 1, 2025. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election."}],"balance_after":22705,"source":{"system":"sec-edgar","filing":"0001127602-25-000425","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000112760225000425/form4.xml","form_type":"4"}},{"id":1486880,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:52:09.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 6, 2025 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.76,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-070811","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000095017024070811/ownership.xml","form_type":"4"}},{"id":1696574,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-02T21:13:50.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":5748,"price":59.86,"value":344075.28,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 1, 2024. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant."}],"balance_after":5748,"derivative":{"exercise_price":59.86,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":5748},"source":{"system":"sec-edgar","filing":"0001127602-24-000120","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000112760224000120/form4.xml","form_type":"4"}},{"id":1696573,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-02T21:13:50.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":3341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock unit was granted on January 1, 2024. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election."}],"balance_after":16438,"source":{"system":"sec-edgar","filing":"0001127602-24-000120","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000112760224000120/form4.xml","form_type":"4"}},{"id":1858872,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T23:34:55.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":16985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":16985,"derivative":{"exercise_price":26.25,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":16985},"source":{"system":"sec-edgar","filing":"0000899243-23-015406","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000089924323015406/doc4.xml","form_type":"4"}},{"id":2068048,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T22:31:39.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":7441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 1, 2023.  The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant."}],"balance_after":7441,"derivative":{"exercise_price":51.71,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":7441},"source":{"system":"sec-edgar","filing":"0000899243-23-000668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000089924323000668/doc4.xml","form_type":"4"}},{"id":2068047,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T22:31:39.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":3867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock unit was granted on January 1, 2023.  The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election."}],"balance_after":13097,"source":{"system":"sec-edgar","filing":"0000899243-23-000668","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000089924323000668/doc4.xml","form_type":"4"}},{"id":2137752,"issuer":{"id":123087,"kind":"organization","name":"COVETRUS, INC.","symbol":"CVET"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-10-13T15:03:39.000Z","date":"2022-10-13","kind":"disposition_to_issuer","acquired":false,"shares":14638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14638},"source":{"system":"sec-edgar","filing":"0001752836-22-000143","document":"wf-form4_166567340597921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000175283622000143/wf-form4_166567340597921.xml","form_type":"4"}},{"id":2137751,"issuer":{"id":123087,"kind":"organization","name":"COVETRUS, INC.","symbol":"CVET"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-13T15:03:39.000Z","date":"2022-10-13","kind":"disposition_to_issuer","acquired":false,"shares":13275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Corgi Merger Sub, Inc. (\"Merger Sub\") with and into the Issuer (the \"Merger\") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. (\"Merger Agreement\"), shares of common stock, par value $0.01 per share, of the Issuer (the \"Shares\" and each a \"Share\"), were converted into the right to receive $21.00 per Share in cash, without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001752836-22-000143","document":"wf-form4_166567340597921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000175283622000143/wf-form4_166567340597921.xml","form_type":"4"}},{"id":2212069,"issuer":{"id":123087,"kind":"organization","name":"COVETRUS, INC.","symbol":"CVET"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-07-06T20:06:57.000Z","date":"2022-07-01","kind":"exercise","acquired":false,"shares":8275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"expiration_date":"2022-07-01","underlying":"Common Stock","underlying_shares":8275},"source":{"system":"sec-edgar","filing":"0001752836-22-000098","document":"wf-form4_165713799617599.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000175283622000098/wf-form4_165713799617599.xml","form_type":"4"}},{"id":2212068,"issuer":{"id":123087,"kind":"organization","name":"COVETRUS, INC.","symbol":"CVET"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-06T20:06:57.000Z","date":"2022-07-01","kind":"exercise","acquired":true,"shares":8275,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13275,"source":{"system":"sec-edgar","filing":"0001752836-22-000098","document":"wf-form4_165713799617599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000175283622000098/wf-form4_165713799617599.xml","form_type":"4"}},{"id":2236082,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:05:32.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":19000,"derivative":{"exercise_price":13.56,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0000899243-22-021890","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000089924322021890/doc4.xml","form_type":"4"}},{"id":2272119,"issuer":{"id":123087,"kind":"organization","name":"COVETRUS, INC.","symbol":"CVET"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-13T20:10:57.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":14638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date."}],"balance_after":14638,"derivative":{"underlying":"Common Stock","underlying_shares":14638},"source":{"system":"sec-edgar","filing":"0001752836-22-000071","document":"wf-form4_165247260944118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000175283622000071/wf-form4_165247260944118.xml","form_type":"4"}},{"id":2277788,"issuer":{"id":109516,"kind":"organization","name":"GELESIS HOLDINGS, INC.","symbol":"GLSH"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T16:17:09.000Z","date":"2022-05-06","kind":"grant","acquired":true,"shares":53832,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement."},{"field":"shares","element":"transactionShares","label":"F2","text":"These RSUs vest in full on March 3, 2023, subject to the reporting person's continued service at such time."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement."}],"balance_after":53832,"source":{"system":"sec-edgar","filing":"0001104659-22-057532","document":"tm2214815d6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805087/000110465922057532/tm2214815d6_4seq1.xml","form_type":"4"}},{"id":2438948,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-11T01:37:57.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":8400,"derivative":{"exercise_price":19,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":8400},"source":{"system":"sec-edgar","filing":"0000899243-22-001527","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000089924322001527/doc4.xml","form_type":"4"}},{"id":2438947,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T01:37:57.000Z","date":"2022-01-06","kind":"purchase","acquired":true,"shares":3947,"price":19,"value":74993.0,"ownership":{"direct":true},"balance_after":3947,"source":{"system":"sec-edgar","filing":"0000899243-22-001527","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000089924322001527/doc4.xml","form_type":"4"}},{"id":2449577,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T02:28:39.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":8554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This represents a non-qualified stock option grant made on 1/1/2022 that vests quarterly over 1 year from the date of grant, subject to continued service as a director, and expires seven years from the date of grant."}],"balance_after":8554,"derivative":{"exercise_price":47.28,"expiration_date":"2029-12-31","underlying":"Common Stock","underlying_shares":8554},"source":{"system":"sec-edgar","filing":"0001127602-22-000726","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000112760222000726/form4.xml","form_type":"4"}},{"id":2449576,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-01-05T02:28:39.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":4230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents a restricted stock unit grant made on 1/1/2022 that fully vest on the first anniversary of the date of grant, subject to continued service as a director."}],"balance_after":9230,"source":{"system":"sec-edgar","filing":"0001127602-22-000726","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000112760222000726/form4.xml","form_type":"4"}},{"id":2606942,"issuer":{"id":123087,"kind":"organization","name":"COVETRUS, INC.","symbol":"CVET"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-11T20:09:10.000Z","date":"2021-08-10","kind":"purchase","acquired":true,"shares":5000,"price":23.24,"value":116200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported constitutes the average weighted price of shares purchased. Shares were purchased at varying prices in the range of $23.05 - $23.37. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001752836-21-000236","document":"wf-form4_162871252039507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000175283621000236/wf-form4_162871252039507.xml","form_type":"4"}},{"id":2641382,"issuer":{"id":123087,"kind":"organization","name":"COVETRUS, INC.","symbol":"CVET"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-07-06T20:03:49.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":8275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date."}],"balance_after":8275,"derivative":{"expiration_date":"2022-07-01","underlying":"Common Stock","underlying_shares":8275},"source":{"system":"sec-edgar","filing":"0001752836-21-000213","document":"wf-form4_162560179895275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000175283621000213/wf-form4_162560179895275.xml","form_type":"4"}},{"id":2925805,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-05T00:31:40.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":27600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on 01/01/2021. The option vests quarterly over 1 year on the last day of each quarter from grant date."}],"balance_after":27600,"derivative":{"exercise_price":57.2,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":27600},"source":{"system":"sec-edgar","filing":"0001127602-21-000261","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000112760221000261/form4.xml","form_type":"4"}},{"id":2978761,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:40:17.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":21289,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21289},"source":{"system":"sec-edgar","filing":"0001104659-20-126315","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126315/a4.xml","form_type":"4"}},{"id":2978760,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:40:17.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":9452,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9452},"source":{"system":"sec-edgar","filing":"0001104659-20-126315","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126315/a4.xml","form_type":"4"}},{"id":2978759,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:40:17.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-20-126315","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126315/a4.xml","form_type":"4"}},{"id":2978758,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-17T15:40:17.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":14676,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-126315","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126315/a4.xml","form_type":"4"}},{"id":3120616,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-05T20:32:27.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":14414,"derivative":{"exercise_price":2.23,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0000899243-20-015456","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000089924320015456/doc4.xml","form_type":"4"}},{"id":3122735,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-04T16:49:12.000Z","date":"2020-06-02","kind":"grant","acquired":true,"shares":21289,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders."}],"balance_after":21289,"derivative":{"exercise_price":8.52,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":21289},"source":{"system":"sec-edgar","filing":"0000792977-20-000058","document":"wf-form4_159130373490595.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000058/wf-form4_159130373490595.xml","form_type":"4"}},{"id":3122734,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T16:49:12.000Z","date":"2020-06-02","kind":"grant","acquired":true,"shares":10269,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) a Change in Control (as defined in the Issuer's Non-Employee Directors' Deferred Compensation Program) of the Issuer and (b) the date of the director's separation from service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":14676,"source":{"system":"sec-edgar","filing":"0000792977-20-000058","document":"wf-form4_159130373490595.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000058/wf-form4_159130373490595.xml","form_type":"4"}},{"id":3152854,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-05-12T21:53:29.000Z","date":"2020-05-08","kind":"purchase","acquired":true,"shares":5000,"price":31.8068,"value":159034.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Open market purchase."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001127602-20-016304","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000112760220016304/form4.xml","form_type":"4"}},{"id":3181712,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-06T21:37:53.000Z","date":"2020-04-02","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted April 2, 2020 and vest as to one-third of the shares underlying the option on each of the first, second and third anniversary of date of grant, subject to continued service."}],"balance_after":37500,"derivative":{"exercise_price":26.13,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001127602-20-013338","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000112760220013338/form4.xml","form_type":"4"}},{"id":3394929,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-10T17:04:35.000Z","date":"2019-10-08","kind":"grant","acquired":true,"shares":9452,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in seven equal monthly installments commencing November 1, 2019."}],"balance_after":9452,"derivative":{"exercise_price":11.58,"expiration_date":"2029-10-08","underlying":"Common Stock","underlying_shares":9452},"source":{"system":"sec-edgar","filing":"0000792977-19-000128","document":"wf-form4_157074145269453.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000128/wf-form4_157074145269453.xml","form_type":"4"}},{"id":3394928,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-10T17:04:35.000Z","date":"2019-10-08","kind":"grant","acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twenty-four equal monthly installments over two years from the date of grant."}],"balance_after":6000,"derivative":{"exercise_price":11.58,"expiration_date":"2029-10-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000792977-19-000128","document":"wf-form4_157074145269453.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000128/wf-form4_157074145269453.xml","form_type":"4"}},{"id":3394927,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-10T17:04:35.000Z","date":"2019-10-08","kind":"grant","acquired":true,"shares":4407,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\") that will vest in seven equal monthly installments beginning on November 1, 2019; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":4407,"source":{"system":"sec-edgar","filing":"0000792977-19-000128","document":"wf-form4_157074145269453.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000128/wf-form4_157074145269453.xml","form_type":"4"}},{"id":3533714,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-09T22:43:51.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 8, 2019 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":14414,"derivative":{"exercise_price":7.99,"expiration_date":"2029-05-07","underlying":"Common Stock","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0000899243-19-012919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000089924319012919/doc4.xml","form_type":"4"}}]}